← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Rapid Micro Biosystems, Inc. (RPID) 10-Year Financial Performance & Capital Metrics

RPID • • Industrial / General
HealthcareMedical DevicesDiagnostic & Imaging EquipmentMicrobial Quality Control Systems
AboutRapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.Show more
  • Revenue $28M +24.6%
  • EBITDA -$47M +12.9%
  • Net Income -$47M +10.6%
  • EPS (Diluted) -1.08 +11.5%
  • Gross Margin -0.39% +98.4%
  • EBITDA Margin -165.97% +30.1%
  • Operating Margin -177.96% +29.2%
  • Net Margin -167.16% +28.3%
  • ROE -48.5% -30.4%
  • ROIC -45.2% -31.1%
  • Debt/Equity 0.08 +31.5%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 11.2%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y11.18%
3Y6.48%
TTM16.63%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM8.48%

EPS CAGR

10Y-
5Y-
3Y-
TTM10.71%

ROCE

10Y Avg-53.64%
5Y Avg-46.75%
3Y Avg-39.65%
Latest-48.68%

Peer Comparison

Microbial Quality Control Systems
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
RPIDRapid Micro Biosystems, Inc.121.06M3.04-2.8124.57%-145.11%-99.91%0.08

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+16.51M16.08M23.23M17.13M22.52M28.05M
Revenue Growth %--0.03%0.45%-0.26%0.31%0.25%
Cost of Goods Sold+16.75M24.15M30.97M25.67M28M28.16M
COGS % of Revenue1.01%1.5%1.33%1.5%1.24%1%
Gross Profit+-234K-8.07M-7.74M-8.54M-5.49M-109K
Gross Margin %-0.01%-0.5%-0.33%-0.5%-0.24%-0%
Gross Profit Growth %--33.49%0.04%-0.1%0.36%0.98%
Operating Expenses+18.4M22.47M39.49M54.68M51.08M49.81M
OpEx % of Revenue1.11%1.4%1.7%3.19%2.27%1.78%
Selling, General & Admin12.97M15.94M29.71M41.81M38.26M35.21M
SG&A % of Revenue0.79%0.99%1.28%2.44%1.7%1.26%
Research & Development5.43M6.53M9.78M12.87M12.82M14.6M
R&D % of Revenue0.33%0.41%0.42%0.75%0.57%0.52%
Other Operating Expenses000000
Operating Income+-18.63M-30.54M-47.23M-63.22M-56.56M-49.92M
Operating Margin %-1.13%-1.9%-2.03%-3.69%-2.51%-1.78%
Operating Income Growth %--0.64%-0.55%-0.34%0.11%0.12%
EBITDA+-17.13M-29.04M-45.7M-60.38M-53.46M-46.56M
EBITDA Margin %-1.04%-1.81%-1.97%-3.52%-2.37%-1.66%
EBITDA Growth %--0.69%-0.57%-0.32%0.11%0.13%
D&A (Non-Cash Add-back)1.5M1.5M1.53M2.84M3.1M3.36M
EBIT-18.37M-33.5M-47.23M-63.22M-56.56M-49.92M
Net Interest Income+-2.38M-3.45M-2.65M1.78M4.21M3.16M
Interest Income0001.78M4.21M3.16M
Interest Expense2.38M3.45M2.65M000
Other Income/Expense-2.11M-6.4M-26.2M1.84M4.13M3.05M
Pretax Income+-20.74M-36.94M-73.43M-61.38M-52.44M-46.87M
Pretax Margin %-1.26%-2.3%-3.16%-3.58%-2.33%-1.67%
Income Tax+427K134K91K-576K31K22K
Effective Tax Rate %1.02%1%1%0.99%1%1%
Net Income+-21.17M-37.08M-73.52M-60.81M-52.47M-46.89M
Net Margin %-1.28%-2.31%-3.16%-3.55%-2.33%-1.67%
Net Income Growth %--0.75%-0.98%0.17%0.14%0.11%
Net Income (Continuing)-21.17M-37.08M-73.52M-60.81M-52.47M-46.89M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)+-0.53-1.17-1.88-1.43-1.22-1.08
EPS Growth %--1.21%-0.61%0.24%0.15%0.11%
EPS (Basic)-0.53-1.17-1.88-1.43-1.22-1.08
Diluted Shares Outstanding39.66M38.67M41.47M42.45M43.02M43.58M
Basic Shares Outstanding39.66M38.67M41.47M42.45M43.02M43.58M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+23.61M62.15M218.12M138.58M120.42M80.92M
Cash & Short-Term Investments12.46M45.08M193.5M108.65M92.05M50.73M
Cash Only12.46M30.08M178.39M27.06M24.29M16.91M
Short-Term Investments015M15.11M81.58M67.77M33.82M
Accounts Receivable4.92M5.78M5.63M5.48M5.58M7.53M
Days Sales Outstanding108.74131.3288.48116.7790.4997.92
Inventory5.75M8.96M15.67M21.19M19.96M20.2M
Days Inventory Outstanding125.37135.51184.67301.22260.17261.83
Other Current Assets336K546K440K705K577K843K
Total Non-Current Assets+8.08M7.85M23.05M52.07M23.04M17.25M
Property, Plant & Equipment7.59M7.05M11.3M20.88M19.07M16.36M
Fixed Asset Turnover2.17x2.28x2.06x0.82x1.18x1.72x
Goodwill000000
Intangible Assets000000
Long-Term Investments152K09.97M29.79M2.91M365K
Other Non-Current Assets332K795K1.77M1.4M1.05M531K
Total Assets+31.69M70M241.17M190.65M143.45M98.17M
Asset Turnover0.52x0.23x0.10x0.09x0.16x0.29x
Asset Growth %-1.21%2.45%-0.21%-0.25%-0.32%
Total Current Liabilities+10.53M15.54M18.17M19.05M18.99M17.57M
Accounts Payable3.21M4.47M3.94M5.43M1.97M2.54M
Days Payables Outstanding69.9967.5346.4877.1725.7232.86
Short-Term Debt000001.21M
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K
Other Current Liabilities2.58M2.88M4.04M3.74M4.95M4.62M
Current Ratio2.24x4.00x12.01x7.27x6.34x4.61x
Quick Ratio1.70x3.42x11.14x6.16x5.29x3.46x
Cash Conversion Cycle164.12199.29226.68340.82324.95326.88
Total Non-Current Liabilities+21.89M29.63M2.02M7.43M6.48M5.25M
Long-Term Debt17.81M24.81M0000
Capital Lease Obligations0007.2M6.21M4.95M
Deferred Tax Liabilities-683K-705K0000
Other Non-Current Liabilities4.08M4.82M2.02M229K263K298K
Total Liabilities32.41M45.18M20.19M26.48M25.46M22.82M
Total Debt+17.81M24.81M07.97M7.35M6.17M
Net Debt5.35M-5.27M-178.39M-19.1M-16.94M-10.74M
Debt / Equity-1.00x-0.05x0.06x0.08x
Debt / EBITDA------
Net Debt / EBITDA------
Interest Coverage-7.85x-8.86x-17.82x---
Total Equity+-725K24.82M220.98M164.17M117.99M75.35M
Equity Growth %-35.23%7.9%-0.26%-0.28%-0.36%
Book Value per Share-0.020.645.333.872.741.73
Total Shareholders' Equity-725K24.82M220.98M164.17M117.99M75.35M
Common Stock4K6K415K421K424K430K
Retained Earnings-204.51M-241.59M-315.11M-375.92M-428.38M-475.27M
Treasury Stock000000
Accumulated OCI01K-16K-1.11M-101K39K
Minority Interest000000

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-21.15M-31M-54.96M-58.55M-45.08M-44.15M
Operating CF Margin %-1.28%-1.93%-2.37%-3.42%-2%-1.57%
Operating CF Growth %--0.47%-0.77%-0.07%0.23%0.02%
Net Income-21.17M-37.08M-73.52M-60.81M-52.47M-46.89M
Depreciation & Amortization1.46M1.51M1.53M2.84M3.1M3.36M
Stock-Based Compensation473K533K1.84M4.02M4.75M0
Deferred Taxes-249K00000
Other Non-Cash Items449K5.14M23.19M728K-1.02M4.14M
Working Capital Changes-2.11M-1.1M-8M-5.33M555K-4.77M
Change in Receivables-511K-1.36M-17K-364K-163K-1.99M
Change in Inventory-3.92M-3.37M-6.77M-5.84M1.19M-335K
Change in Payables1.03M978K-524K1.48M-3.46M562K
Cash from Investing+-1.7M-15.67M-13.29M-93.47M42.15M36.66M
Capital Expenditures-1.7M-690K-3.22M-6.74M-1.84M-1.36M
CapEx % of Revenue0.1%0.04%0.14%0.39%0.08%0.05%
Acquisitions------
Investments------
Other Investing0020K000
Cash from Financing+14.87M64.23M216.75M693K149K203K
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid000000
Share Repurchases------
Other Financing0-2.2M-940K726K186K0
Net Change in Cash------
Free Cash Flow+-22.84M-31.69M-58.18M-65.29M-46.93M-45.52M
FCF Margin %-1.38%-1.97%-2.5%-3.81%-2.08%-1.62%
FCF Growth %--0.39%-0.84%-0.12%0.28%0.03%
FCF per Share-0.58-0.82-1.40-1.54-1.09-1.04
FCF Conversion (FCF/Net Income)1.00x0.84x0.75x0.96x0.86x0.94x
Interest Paid01.98M2.59M42K38K0
Taxes Paid000000

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)--307.77%-59.82%-31.58%-37.19%-48.5%
Return on Invested Capital (ROIC)-302.37%-189.51%-114.01%-50.53%-34.47%-45.2%
Gross Margin-1.42%-50.2%-33.32%-49.85%-24.36%-0.39%
Net Margin-128.22%-230.63%-316.48%-354.91%-232.99%-167.16%
Debt / Equity-1.00x-0.05x0.06x0.08x
Interest Coverage-7.85x-8.86x-17.82x---
FCF Conversion1.00x0.84x0.75x0.96x0.86x0.94x
Revenue Growth--2.63%44.5%-26.25%31.44%24.57%

Revenue by Segment

2021202220232024
Product-11.06M20.06M21.04M
Product Growth--81.44%4.89%
Service-6.08M7.94M9.32M
Service Growth--30.72%17.36%
Government Contract----
Government Contract Growth----
Product and service revenue - non-recurring13.82M---
Product and service revenue - non-recurring Growth----
Product and service revenue - recurring7.82M---
Product and service revenue - recurring Growth----
Non-commercial revenue - non-recurring1.59M---
Non-commercial revenue - non-recurring Growth----

Revenue by Geography

2021202220232024
UNITED STATES-8.77M9.88M10.64M
UNITED STATES Growth--12.68%7.69%
All Other Countries-2.96M3.97M6.64M
All Other Countries Growth--33.98%67.43%
SWITZERLAND-2.76M4M5.67M
SWITZERLAND Growth--44.96%41.88%
GERMANY-2.65M2.12M3.05M
GERMANY Growth---20.12%44.09%
JAPAN--2.56M2.05M
JAPAN Growth----19.87%
United states12.89M---
United states Growth----
All other countries4.33M---
All other countries Growth----
Switzerland4.31M---
Switzerland Growth----
Germany1.7M---
Germany Growth----

Frequently Asked Questions

Growth & Financials

Rapid Micro Biosystems, Inc. (RPID) reported $30.5M in revenue for fiscal year 2024. This represents a 85% increase from $16.5M in 2019.

Rapid Micro Biosystems, Inc. (RPID) grew revenue by 24.6% over the past year. This is strong growth.

Rapid Micro Biosystems, Inc. (RPID) reported a net loss of $44.3M for fiscal year 2024.

Dividend & Returns

Rapid Micro Biosystems, Inc. (RPID) has a return on equity (ROE) of -48.5%. Negative ROE indicates the company is unprofitable.

Rapid Micro Biosystems, Inc. (RPID) had negative free cash flow of $38.6M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.